Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes

Background: Graft hypertrophy is a common occurrence after periosteal, collagen-covered and matrix-induced autologous chondrocyte implantation (MACI). Purpose/Hypothesis: The purpose of this study was to investigate the incidence, development, and degree of graft hypertrophy at 24 months after MACI....

Full description

Bibliographic Details
Main Authors: Ebert, J., Smith, Anne, Fallon, M., Butler, R., Nairn, R., Breidahl, W., Wood, D.
Format: Journal Article
Published: SAGE Publications Inc. 2015
Online Access:http://hdl.handle.net/20.500.11937/9390
_version_ 1848745935994093568
author Ebert, J.
Smith, Anne
Fallon, M.
Butler, R.
Nairn, R.
Breidahl, W.
Wood, D.
author_facet Ebert, J.
Smith, Anne
Fallon, M.
Butler, R.
Nairn, R.
Breidahl, W.
Wood, D.
author_sort Ebert, J.
building Curtin Institutional Repository
collection Online Access
description Background: Graft hypertrophy is a common occurrence after periosteal, collagen-covered and matrix-induced autologous chondrocyte implantation (MACI). Purpose/Hypothesis: The purpose of this study was to investigate the incidence, development, and degree of graft hypertrophy at 24 months after MACI. The hypothesis was that graft hypertrophy would not be associated with clinical outcome at 24 months. Study Design: Case series, Level of evidence, 4. Methods: This study was undertaken in 180 consecutive patients (113 male, 67 female) after MACI in the knee. All patients were assessed clinically using the Knee injury and Osteoarthritis Outcome Score (KOOS) and underwent magnetic resonance imaging (MRI) at 3, 12, and 24 months after surgery. The incidence of hypertrophy relevant to anatomic graft site was investigated, as was the progressive change in hypertrophic studies postoperatively. The degree of tissue overgrowth in hypertrophic cases was investigated, as was its association with patient clinical outcome at 24 months after surgery. Results: Of the 180 patients, 50 demonstrated a hypertrophic graft at 1 or more postoperative time points. This included 9 grafts (5.0%) at 3 months and 32 grafts (18.7%) at 12 months. At 24 months, 47 grafts (26.1%) - 43 (32.1%) tibiofemoral and 4 (8.7%) patellofemoral - were hypertrophic. Patients with hypertrophic grafts at 24 months (n = 47) were younger (P =.051), they had a lower body mass index (BMI; P =.069), and significantly fewer of them had patellofemoral grafts (P =.007) compared with patients who had grafts with full (100%) tissue infill (n = 61). There were no significant differences in any of the KOOS subscales between patients with graft hypertrophy or full (100%) tissue infill at 24 months after surgery, while the severity of graft hypertrophy was not associated with KOOS subscales at 24 months. Conclusion: Hypertrophic grafts after MACI were common and continued to develop through to 24 months after surgery. Hypertrophic growth was associated with being younger and having a lower BMI, was more common on the femoral condyles, and overall was not associated with clinical outcome at 24 months after surgery. However, further research with longer term follow-up is required to evaluate the effect of persistent hypertrophy on graft stability and to assess the use of early surgical intervention to prevent such failure.
first_indexed 2025-11-14T06:25:16Z
format Journal Article
id curtin-20.500.11937-9390
institution Curtin University Malaysia
institution_category Local University
last_indexed 2025-11-14T06:25:16Z
publishDate 2015
publisher SAGE Publications Inc.
recordtype eprints
repository_type Digital Repository
spelling curtin-20.500.11937-93902017-09-13T14:52:04Z Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes Ebert, J. Smith, Anne Fallon, M. Butler, R. Nairn, R. Breidahl, W. Wood, D. Background: Graft hypertrophy is a common occurrence after periosteal, collagen-covered and matrix-induced autologous chondrocyte implantation (MACI). Purpose/Hypothesis: The purpose of this study was to investigate the incidence, development, and degree of graft hypertrophy at 24 months after MACI. The hypothesis was that graft hypertrophy would not be associated with clinical outcome at 24 months. Study Design: Case series, Level of evidence, 4. Methods: This study was undertaken in 180 consecutive patients (113 male, 67 female) after MACI in the knee. All patients were assessed clinically using the Knee injury and Osteoarthritis Outcome Score (KOOS) and underwent magnetic resonance imaging (MRI) at 3, 12, and 24 months after surgery. The incidence of hypertrophy relevant to anatomic graft site was investigated, as was the progressive change in hypertrophic studies postoperatively. The degree of tissue overgrowth in hypertrophic cases was investigated, as was its association with patient clinical outcome at 24 months after surgery. Results: Of the 180 patients, 50 demonstrated a hypertrophic graft at 1 or more postoperative time points. This included 9 grafts (5.0%) at 3 months and 32 grafts (18.7%) at 12 months. At 24 months, 47 grafts (26.1%) - 43 (32.1%) tibiofemoral and 4 (8.7%) patellofemoral - were hypertrophic. Patients with hypertrophic grafts at 24 months (n = 47) were younger (P =.051), they had a lower body mass index (BMI; P =.069), and significantly fewer of them had patellofemoral grafts (P =.007) compared with patients who had grafts with full (100%) tissue infill (n = 61). There were no significant differences in any of the KOOS subscales between patients with graft hypertrophy or full (100%) tissue infill at 24 months after surgery, while the severity of graft hypertrophy was not associated with KOOS subscales at 24 months. Conclusion: Hypertrophic grafts after MACI were common and continued to develop through to 24 months after surgery. Hypertrophic growth was associated with being younger and having a lower BMI, was more common on the femoral condyles, and overall was not associated with clinical outcome at 24 months after surgery. However, further research with longer term follow-up is required to evaluate the effect of persistent hypertrophy on graft stability and to assess the use of early surgical intervention to prevent such failure. 2015 Journal Article http://hdl.handle.net/20.500.11937/9390 10.1177/0363546515591257 SAGE Publications Inc. restricted
spellingShingle Ebert, J.
Smith, Anne
Fallon, M.
Butler, R.
Nairn, R.
Breidahl, W.
Wood, D.
Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes
title Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes
title_full Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes
title_fullStr Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes
title_full_unstemmed Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes
title_short Incidence, Degree, and Development of Graft Hypertrophy 24 Months after Matrix-Induced Autologous Chondrocyte Implantation: Association with Clinical Outcomes
title_sort incidence, degree, and development of graft hypertrophy 24 months after matrix-induced autologous chondrocyte implantation: association with clinical outcomes
url http://hdl.handle.net/20.500.11937/9390